CJC-1295 /Ipamorelin (Blend) – 10mg(Total)
B's Research Labs | Research Overview
B's Research Labs CJC-1295 without DAC / Ipamorelin is a dual-peptide research formulation combining two synthetic compounds with distinct molecular structures and receptor-binding characteristics. CJC-1295 without DAC, also known as Modified GRF (1–29), is a synthetic 29-amino-acid analogue of growth hormone–releasing hormone (GHRH). Ipamorelin is a synthetic pentapeptide characterized by its interaction with growth hormone secretagogue receptors (GHSR). This combination is of interest in peptide chemistry, molecular biology, receptor-binding studies, and biochemical research involving distinct peptide signaling pathways. Supplied in a lyophilized powder format containing 5 mg of CJC-1295 without DAC and 5 mg of Ipamorelin (10 mg total peptide content), this formulation is intended exclusively for controlled laboratory research and analytical applications. Laboratory investigations may focus on peptide stability, molecular structure, receptor-binding characteristics, compound compatibility, biochemical interactions, and the individual and combined behavior of both peptides under controlled experimental conditions. Research involving these compounds may also examine GHRH and GHSR receptor signaling pathways. Such investigations remain experimental and do not establish clinical safety, efficacy, or suitability for administration.
RUO — RESEARCH USE ONLY
For in vitro laboratory research and analytical applications only.
NOT FOR HUMAN OR VETERINARY USE. NOT FOR CONSUMPTION, INJECTION, INGESTION, OR CLINICAL ADMINISTRATION.
Not intended for diagnostic, therapeutic, pharmaceutical, cosmetic, or personal use. No claims are made regarding safety, efficacy, compatibility, or suitability for human or animal applications.
Compound Identification
CJC-1295 without DAC / Ipamorelin is a dual-peptide research blend containing 5 mg of Modified GRF (1–29) and 5 mg of Ipamorelin, for a total of 10 mg of peptide compounds per vial.
